Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Haematopoietic Cell Transplantation: Extended Follow-Up of the Phase 2 Multi-Cohort CheckMate 205 Study

被引：0

作者：

Collins, G. ^{[1
]}

Armand, P. ^{[2
]}

Engert, A. ^{[3
]}

Younes, A. ^{[4
]}

Lee, H. J. ^{[5
]}

Santoro, A. ^{[6
]}

Zinzani, P. L. ^{[7
]}

Timmerman, J. ^{[8
]}

Ramchandren, R. ^{[9
]}

Cohen, J. ^{[10
]}

De Boer, J. P. ^{[11
]}

Savage, K. ^{[12
]}

Kuruvilla, J. ^{[13
,14
]}

Trneny, M. ^{[15
,16
]}

Shipp, M. ^{[2
]}

Sacchi, M. ^{[17
]}

Sumbul, A. ^{[17
]}

Ansell, S. ^{[18
]}

机构：

[1] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Univ Hosp Cologne, Cologne, Germany

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Humanitas Univ, Humanitas Canc Ctr, Milan, Italy

[7] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy

[8] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA

[9] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[11] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands

[12] BC Canc, Vancouver, BC, Canada

[13] Univ Toronto, Vancouver, BC, Canada

[14] Princess Margaret Canc Ctr, Vancouver, BC, Canada

[15] Charles Univ Prague, Prague, Czech Republic

[16] Gen Univ Hosp Prague, Prague, Czech Republic

[17] Bristol Myers Squibb, Princeton, NJ USA

[18] Mayo Clin, Rochester, MN USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷

关键词：

checkpoint inhibitor; Hodgkin lymphoma; long-term outcomes; programmed death-1;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH19-PO-0

引用

页码：80 / 81

页数：2

共 50 条

[1] Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial
Jaeger, U.
Engert, A.
Fanale, M.
Santoro, A.
Armand, P.
Ansell, S.
Zinzani, P. L.
Timmerman, J. M.
Collins, G. P.
Ramchandren, R.
Cohen, J. B.
De Boer, J. P.
Kuruvilla, J.
Savage, K. J.
Trneny, M.
Rodig, S.
Shipp, M.
Kato, K.
Sumbul, A.
Farsaci, B.
Younes, A.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 13 - +
[2] NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL
Engert, A.
Fanale, M.
Santoro, A.
Armand, P.
Ansell, S.
Zinzani, P. L.
Timmerman, J.
Collins, G.
Ramchandren, R.
Cohen, J.
De Boer, J. P.
Kuruvilla, J.
Savage, K.
Trneny, M.
Rodig, S.
Shipp, M.
Kato, K.
Sumbul, A.
Farsaci, B.
Younes, A.
HAEMATOLOGICA, 2017, 102 : 145 - 145
[3] Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study
Armand, Philippe
Engert, Andreas
Younes, Anas
Lee, Hun Ju
Santoro, Armando
Zinzani, Pier Luigi
Timmerman, John M.
Collins, Graham P.
Ramchandren, Radhakrishnan
Cohen, Jonathon B.
De Boer, Jan Paul
Savage, Kerry J.
Kuruvilla, John
Trneny, Marek
Shipp, Margaret A.
Sacchi, Mariana
Ansell, Anne Sumbuland Stephen M.
Ansell, Stephen M.
BLOOD, 2018, 132
[4] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Armand, Philippe
Engert, Andreas
Younes, Anas
Fanale, Michelle
Santoro, Armando
Zinzani, Pier Luigi
Timmerman, John M.
Collins, Graham P.
Ramchandren, Radhakrishnan
Cohen, Jonathon B.
De Boer, Jan Paul
Kuruvilla, John
Savage, Kerry J.
Trneny, Marek
Shipp, Margaret A.
Kato, Kazunobu
Sumbul, Anne
Farsaci, Benedetto
Ansell, Stephen M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) : 1428 - +
[5] Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study
Cohen, Jonathon B.
Kuruvilla, John
Engert, Andreas
Ansell, Stephen M.
Younes, Anas
Lee, Hun Ju
Trneny, Marek
Savage, Kerry J.
Ramchandren, Radhakrishnan
Collins, Graham P.
Zinzani, Pier Luigi
De Boer, Jan Paul
Shipp, Margaret A.
Santoro, Armando
Timmerman, John M.
Sacchi, Mariana
Sy, Oumar
Armand, Philippe
BLOOD, 2018, 132
[6] Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Timmerman, John M.
Engert, Andreas
Younes, Anas
Santoro, Armando
Armand, Philippe
Fanale, Michelle A.
Collins, Graham P.
Ratanatharathorn, Voravit
Kuruvilla, John
Cohen, Jonathon B.
Savage, Kerry J.
Trneny, Marek
De Boer, Jan Paul
Shipp, Margaret A.
Rodig, Scott J.
Kato, Kazunobu
Sumbul, Anne
Ansell, Stephen
BLOOD, 2016, 128 (22)
[7] Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
Momotow, Jesko
Goergen, Helen
Behringer, Karolin
Broeckelmann, Paul J.
Borchmann, Sven
Tresckow, Bastian V.
Kobe, Carsten
Engert, Andreas
Sasse, Stephanie
HEMASPHERE, 2019, 3 (05):
[8] Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study
Engert, Andreas
Taylor, Fiona
Bennett, Bryan
Chen, Clara
Cocks, Kim
McDonald, Jeffrey
Mann, Erin
Sacchi, Mariana
Cella, David
BLOOD, 2017, 130
[9] CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN
Engert, A.
Santoro, A.
Shipp, M.
Zinzani, P. L.
Timmerman, J.
Ansell, S.
Armand, P.
Fanale, M.
Ratanatharathorn, V.
Kuruvilla, J.
Cohen, J.
Collins, G.
Savage, K.
Trneny, M.
Kato, K.
Farsaci, B.
Parker, S.
Rodig, S.
Younes, A.
HAEMATOLOGICA, 2016, 101 : 319 - 319
[10] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (vol 36, pg 1428, 2018)
Armand
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) : 2748 - 2748

← 1 2 3 4 5 →